Disc Medicine, Inc.
Disc Medicine, Inc. (Nasdaq: IRON) is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases, with product candidates targeting pathways involved in red blood cell formation and function, particularly heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin… From the company’s description.
In fiscal 2025, Disc Medicine, Inc. reported a net loss of $212.18M. Operations used $180.39M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Disc Medicine, Inc. does
In the company’s own words
Disc Medicine, Inc. (Nasdaq: IRON) is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases, with product candidates targeting pathways involved in red blood cell formation and function, particularly heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias, including EPP and XLP; DISC-0974 for anemia associated with myelofibrosis and inflammatory bowel disease; DISC-3405 for polycythemia vera, sickle cell disease and other blood disorders; and preclinical DISC-0998 for anemia associated with inflammatory diseases. The company’s development programs are organized around heme biosynthesis modulation and iron homeostasis, with candidates designed to reduce toxic heme-pathway metabolites, increase iron availability to address anemia, or restrict iron to reduce excessive red blood cell production. Disc was founded in 2017 and has built its portfolio through internal research and licensing agreements, including rights to bitopertin from Roche. Its website is https://www.discmedicine.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1816736
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Disc Medicine, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Disc Medicine, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Disc Medicine, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Disc Medicine, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Disc Medicine, Inc.'s last four quarterly filings that the numbers alone won't show?”